Stephen B. Williams MD, MS, FACSChief, Division of Urology; Professor (Tenured), Urology and Radiology, Robert Earl Cone Professorship, Director of Urologic Oncology Director of Urologic Research, Co-Director of the Surgical Outcomes Research Division, The University of Texas Medical Branch, Galveston, Texas
Dr. Stephen B. Williams is Chief, Division of Urology, Professor (Tenured), Robert Earl Cone Endowed Professorship, Director of Urologic Oncology, Director of Urologic Research and Co-Director for the Department of Surgery Clinical Outcomes Research Program at the University of Texas Medical Branch at Galveston. Dr. Williams is also the Medical Director for High-Value Care for UTMB Health System. He completed Urology residency at Harvard Medical School’s Brigham and Women’s Hospital followed by a Society of Urologic Oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Williams is currently a member of many national societies, which include the American Urological Association, European Association of Urology, Society International Urology, Society of Urologic Oncology and the American Society of Clinical Oncology. He serves on the board for the Society of Robotic Surgery, International Bladder Cancer Network, International Bladder Cancer Group, and is chair for the Society International Urology Enhanced Recovery After Surgery (ERAS) Initiative. He is currently a reviewer for numerous journals including the Journal of the American Medical Association, Journal of Urology, European Urology, Urology, Urologic Oncology and the BJU (section editor for bladder cancer). His research has been awarded Best Research Award at the 2016 annual AUA meeting and more recently at the 2018 33rd Annual EAU Congress in Copenhagen. He is the author of over 200 peer-reviewed manuscripts and book chapters dedicated to urologic oncology and health services research.
Dr. Williams has made a significant impact on urology through his seminal research in comparative effectiveness regarding bladder cancer treatments. His important work has carefully examined costs and outcomes in regards to optimizing current treatments for bladder cancer. He has previously been invited to present his work at the Institute of Medicine in Washington, DC to help guide health policy decision-making. His research focus is identifying at-risk bladder cancer patients and interventions to improve bladder cancer survival. This research is supported by a Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Cancer Research Program (PRCRP) Career Development Award (CA160108).